Pfizer (PFE) Valuation Check After HYMPAVZI Expansion And Positive Pneumococcal Vaccine Data

Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and ...

Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)

Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate ...

Pfizer expands pneumococcal vaccine push with new programs

Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...
FierceBiotech

Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3. The move follows a phase 2 win last ...

Pfizer begins late-stage trial for new pneumococcal shot in infants after strong Phase 2 data

Pfizer (PFE) stock is in focus as the company starts Phase 3 infant trials for the 25-valent pneumococcal vaccine after ...
Benzinga.com

CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines

On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted for expanded usage recommendation for Merck & Co Inc’s (NYSE:MRK) ...